STAKEHOLDER PERSPECTIVES

TRENDS AND OPPORTUNITIES IN HEALTH ECONOMIC EVALUATIONS OF PROSTHETIC CARE INNOVATIONS

Frossard L1

1 YourResearchProject Pty Ltd, Brisbane, Australia.

ABSTRACT

Overcoming obstacles to prosthetic fittings requires frequent tryouts of sockets and components. Repetitions of interventions are upsetting for users and place substantial economic burden on healthcare systems. Encouraging prosthetic care innovations capable of alleviating clinical and financial shortcomings of socket-based solutions is essential. Nonetheless, evidence of socio-economic benefits of an innovation are required to facilitate access to markets. Unfortunately, complex decisions must be made when allocating resources toward the most relevant health economic evaluation (HEE) at a given stage of development of an innovation. This paper first, aimed to show the importance and challenges of HEEs of intervention facilitating prosthetic fittings. Next, the main trends in HEEs at various phases of product development and clinical acceptance of prosthetic care innovations were outlined. Then, opportunities for a basic framework of a preliminary cost-utility analysis (CUA) during the mid-stage of development of prosthetic care innovations were highlighted. To do this, fundamental and applied health economic literature and prosthetic-specific publications were reviewed to extract and analyse the trends in HEEs of new medical and prosthetic technologies, respectively. The findings show there is consensus around the weaknesses of full CUAs (e.g., lack of timeliness, resource-intensive) and strengths of preliminary CUAs (e.g., identify evidence gaps, educate design of full CUA, fast-track approval). However, several obstacles must be overcome before preliminary CUA of prosthetic care innovations will be routinely carried out. Disparities of methods and constructs of usual preliminary CUA are barriers that could be alleviated by a more standardized framework. The paper concludes by identifying that there are opportunities for the development of a basic framework of preliminary CUAs of prosthetic care innovations. Ultimately, the collaborative design of a framework could simplify selection of the methods, standardise outcomes, ease comparisons between innovations and streamline pathways for adoption. This might facilitate access to economical solutions that could improve the life of individuals suffering from limb loss.

INTRODUCTION

Alfred Nobel (1833-1896) said the following about innovation “If I have a thousand ideas and only one turns out to be good, I am satisfied.”

In healthcare, the difference between a “good” or a not so good innovation is made during health technology assessment (HTA) and/or health economic evaluation (HEE). As defined in APPENDIX 1, these evaluations aim at understanding what is the value for money of a treatment. Simply put, payers want to make sure they get a bang for their buck!

This is tough question because the answer is rarely black and white. Nonetheless, addressing any concerns with socio-economic value of an intervention is a prerequisite to warrant access to market. Great but unaffordable treatments have little prospect of being adopted by healthcare policymakers.

The paper deals with issues of health economic assessments specific to prosthetic care innovations as...
presented in Figure 1. First, the importance and challenges of HEEs of interventions facilitating prosthetic fittings are highlighted. Next, the main trends in HEEs of new healthcare technologies are outlined with particular emphasis on specific HEEs to consider during the course of development of innovations. Then, opportunities for a basic framework of preliminary assessments during the mid-stage of development of prosthetic care innovations are suggested. Finally, the paper concludes with some calls to action to further develop preliminary assessments.

IMPORTANCE OF HEALTH TECHNOLOGY EVALUATIONS

This introductory section highlighted (A) the needs for solutions facilitating prosthetic fittings and (B) the current challenges to produce relevant health economic evaluations of prosthetic care innovations.

Role of prosthetic care

Because the everyday ability of individuals suffering from limb loss to use an artificial limb is critical to their quality of life, clinical teams made bespoke recommendations intending to maximize comfort, stability and mobility of prosthetic fittings.\(^2\)\(^,\)\(^3\) Ultimately, this process incorporates all personalized interventions performed by a prosthetist around the choice and alignment of prosthetic components as well as the management of prosthetic attachment to the residuum including design, manufacture and adjustment of socket or osseointegrated implant.\(^4\)

Outcomes of prosthetic fitting depends largely on the performance of prosthetic components,\(^5\)\(^-\)\(^11\) where Dillingham et al (2001) noted that 60% of amputees are satisfied with prosthetic characteristics such as weight, aesthetics and functionality (e.g. servicing, how easy the prosthesis is to use) and 57% of the traumatic lower limb amputees in the study expressed some dissatisfaction with prosthetic comfort.\(^12\) Since, studies showed that the use and satisfaction of prosthetic lower limb could be significantly improved when using advanced components such microprocessor-controlled knees compared to a non-microprocessor-controlled knees.\(^9\)\(^,\)\(^13\)\(^,\)\(^14\)

![Figure 1: Overview of importance, trends and gaps of health economy evaluations (HEE) of prosthetic solutions leading to the need for basic framework of preliminary (Pre) cost-utility analysis (CUA) for prosthetic care innovations.](image-url)
Satisfactory prosthetic fitting might be compromised because of incongruous shapes of residuum (e.g., length, bulbous, volume change) and/or skin issues. 16-18 Paterno et al (2018) and Meulenbelt et al (2009) report that 63–82% of lower limb amputees have problems with skin lesions. 2,18 Turner and McGregor (2020) report that 48.0% of amputees and 65.7% of clinicians cited socket fit issues as the biggest factor impacting rehabilitation. 6 And, sadly, Paterno et al (2018) and Meulenbelt et al (2009) found a 25–57% prosthetic abandonment rate and identified failed socket fit as a likely possible cause. 2,18

**Demand for prosthetic care innovations**

In many cases, overcoming obstacles to prosthetic fitting requires frequent tryouts of components and sockets fittings. 3 Regular medical attention are, first and foremost, upsetting (e.g., pain), disruptive (e.g., sick leave) and costly (e.g., out-of-pocket expenses) for users. 19 Repetitions of interventions also place a substantial economic burden on healthcare systems stressed to subsidize treatments beyond minimal prosthetic care standards. 20–22 For example, the fitting of only a single socket per year might be approved by some healthcare organizations. 22

Encouraging prosthetic care innovations that alleviate the clinical and financial shortcomings of current fitting options is essential (APPENDIX 1). 2,3,14,23–26 Hence, efforts made by a bench of stakeholders (e.g., users, carers, clinicians, engineers, researchers, administrators) to develop and encourage new prosthetic care interventions to improve socket fittings and, eventually, eliminate socket attachments altogether (e.g., bone-anchored prostheses). 27–34 These solution-finders will be called “promoters” of prosthetic care innovations throughout this paper and are shown in relationship to other concepts presented in this paper as a regrouping of individuals suffering from limb loss, providers of prosthetic solutions and administrators of healthcare organisations (APPENDIX 1) into a single collaborative group with common goals. 22,35–38

Ultimately, prosthetic care innovations must be safe and efficient in ways that alleviate some adverse events (e.g., pain, slippage, pistoning, bell clapping, skin damages, falls), maximise functional outcomes (e.g., comfort, stability, mobility) and, preferably, enhance quality of life (e.g., Quality-Adjusted Life Year, Disability-Adjusted Life Year). 2,3,14,23–25,29,39,40 Proofs of safety and efficacy of innovations are essential but no longer sufficient. 11 Evidence of socio-economic benefits are also paramount. 4,30,37,38,41–47

**Health economic evaluations of innovations**

Ijzerman and Steuten (2011) identified that in order for societal benefits to be maximized three things must occur: 1) governments need more data on benefits arising when public resources are spent, 2) companies need more data to effectively manage their product development portfolios and 3) research programs at universities may need to be actively encouraged in this direction. 37

Policymakers in healthcare organizations around the world adopt a reasoning more or less utilitarian when making decisions about medical care expenses. 37 However, healthcare administrators are often obligated to confirm the value for money of interventions prior approval (e.g. fee-for-service, fee-for-value). 47–53 For example, an HEE might be required to differentiate the four microprocessor-controlled knees assessed by Campbell et al (2020) all showing relative parity with regards to functional mobility, health state satisfaction and quality of life or injurious falls (i.e., C-Leg, Ottobock, Duderstadt, Germany; Orion, Blatchford Group, Hampshire, United Kingdom; Plie, Freedom Innovations, Irvine, California, United States; Rheo, Ossur, Reykjavik, Iceland). 14 Recommendation for one knee or the other may be based on costs reduction of prosthetic care interventions.

The burden of HEE of an innovation also falls onto developers and manufacturers of technological solutions including attachments (e.g., liners, sockets, implants), artificial limb components (e.g., elbow, wrist, knee, ankle) and protective device (e.g., shock absorbers, failsafe). 38 Steven et al (2019) suggested that solution developers must understand the value created by their interventions and act quickly on them to provide some forms of evidence of cost-effectiveness of their innovations. 48 Failing to do so could seriously hinder access to market and adoption of their innovations. O’Malley (2010) indicated that the most common reason for the Australian Medical Services Advisory Committee to not recommend funding for new technology was not only insufficient clinical evidence but also the lack of proven cost-effectiveness presented during early stage of the examination process. 54

**Making decisions about economic evaluations**

Steven et al (2019) stated that HEE can be approached in a number of ways. They identified a range of approaches to compare the costs of health care services and possible cost savings which observe the consequences of an intervention and the effectiveness of that same intervention through a lens of outcomes that are valued patients, payers and providers, or which align with widely used global utility measures. 48 They specified that the value of a prosthetic care intervention could be assessed using a range of cost-benefit, cost-consequence, cost-effectiveness and cost-utility analyses considering valuations of costs (e.g., monetary units) and a range of benefits. Ijzerman and Steuten (2011) specified that no single method will produce the right information for all decision makers. Each method has advantages and disadvantages and work for specific applications, as opposed to all applications. 37 They suggested that a toolbox of methods must be used.
Unfortunately, the multitude of HEEs often leave promoters making challenging decisions around allocation of sufficient resources toward the most relevant HEE approach at a given point of an innovation development. Facilitating this decision-making process would start with an overview of the trends and specific ways HEEs can be done at various stages of development of an innovation.

CURRENT TRENDS IN HEALTH TECHNOLOGY EVALUATIONS

This second section (A) reviewed generic pathways to assess health economic consequences of a new treatment at a given stage of product development and clinical acceptance and (B) highlighted selected studies that followed these pathways to assess prosthetic care interventions.

Key concepts of health economic evaluations

As described in APPENDIX 1, HEE include, but not limited to, cost-effectiveness analyses (CEA) or cost-utility analyses (CUA). These terms are often used interchangeably although they are technically looking at different types of utilities. CEA is concerned with a particular functional outcome of a treatment (e.g., walking speed). CUA relies on self-reported quality of life status measured using standard surveys such as EQ-5D or 36-Item Short Form Survey (SF36). CUA comparing usual and new treatments involve incremental cost-utility ratio (ICUR) based on incremental costs and utilities over time that could be compared to cost-effectiveness (CET) or, more often, willingness-to-pay (WTP) thresholds.1,48,55

Patient-centred assessments of global health-related quality of life might be influenced by prosthetic care to a certain extent. Therefore, these metrics might reflect only partially the benefits of a prosthetic intervention. However, outcomes of CUA reported in monetary units per quality-adjusted life-year (QALY) can be easily compared across other medical interventions or disease states. CUA are commonly used to facilitate effective communication among healthcare professionals.48,56,57

Health economic evaluations pathways

Promoters can be informed by an abundance of health economic research focusing on a broad range of fundamental and applied HEEs issues that could be more or less relevant (e.g., difference between pharmaceutical and medical technologies).54,58 Some studies provided valuable insights into ways outcomes of HEEs can facilitate the approval process of an innovation by a particular governmental healthcare system (e.g., Australian).53,54,59-61 Others explained the basic concepts of HEEs to clinicians and prosthetic care providers.48,56,57 Several landmark studies presented prosthetic-specific HEEs.21,50-52,61-74

Two studies were of particular interest because they can assist promoters to make an educated decision when choosing an HEE accordingly to the level of innovation development. Ijzerman and Steuten (2011) systematically described that early, preliminary and full CUAs can be conducted at the early, mid and late stage of clinical acceptance of any medical treatment, respectively.37 More recently, new insights were provided by Kannenberg and Seidinger (2019) who explained how these three types of CUAs should also be performed by prosthetic manufacturers at early, mid and late phase development of a prosthetic product.38 The authors indicated that CUA during the product’s life cycle is beneficial in three ways. It allows potential cost-effectiveness to be estimated and included in investment decision processes and mitigates the risk of investing in technology unlikely to be cost-effective. It helps to prioritize between competing cost-effective concepts or technologies. It facilitates the identification of parameters having the largest impact on the likely cost-effectiveness of the product to be identified in order to best manage limited research funds.38

Figure 2 gives an overview synthesizing both approaches. Decision uncertainty and strength of evidence were suggested for early, preliminary and full CUAs during early, mid and late phase of product development (manufacturer’s perspective) and clinical acceptance (healthcare’s perspective) of prosthetic care innovations, respectively.

Next, the general principle, expected capacity to address Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and Consensus Health Economic Criteria (CHEC) extended checklists, typical strengths and weaknesses as well as selected examples of prosthetic-focused CUAs.75-77 is briefly described. The decision was made to present the CUAs as they historically gained recognition starting from full, to preliminary and early CUAs rather than following the sequential timeline of their implementation. Appraisal of each type of CUAs using the CHEERS and CHEC-extended checklists were detailed in Supplementary material.

Full cost-utility analyses

Traditionally, mainstream HEEs involved comprehensive or “full” CUAs essentially produced when innovations are gaining clinical acceptance after commercialisation. Full CUAs can be conducted from societal and/or healthcare perspectives. These CUAs usually rely on primary costs extracted from financial records expressed in monetary units as well as utilities measured by quality of life surveys expressed in QALY for cohorts of participants over an extended period of time (APPENDIX 1).48,50-53,62,78,79 Costs, utilities and ICURs are projected using Bayesian or Markov models based on plausible information extracted from primary studies for a series of scenarios over scalable time horizons (e.g., Years, decades, lifetime).1,37,63,64,70,78,80,81
It was postulated that conventional full CUA s should address strongly all items of the CHEERS and CHEC-extended checklists (Table 1, Table 2).

Modelling CUA s can be comprehensive because of the breadth (e.g., scenarios) and depth (e.g., time horizon) of their analysis. Furthermore, uncertainty and sensibility of outcomes, shown by the size of the errors around the point estimates due to data sources (e.g., sample size) and/or to the process of evaluation (APPENDIX 1), tend to be well worked out and, possibly, relatively low compared to early and preliminary CUA s. Therefore, full CUA provide strong evidence supporting robust recommendations considered by decision makers (e.g., approval for funding).

However, modelling CUA s require substantial resources. Building models is labour intensive (e.g., determine scenarios, test assumptions). More importantly, Kannenberg and Seidinger (2019) noted the necessity of requiring the inclusion of outcome parameters, like health-related quality of life, in these models. This means that full CUA s produce their best outcomes when sufficient costs and utilities are known for large cohorts over an extended length of time in a given jurisdiction (e.g., within-trial and beyond-trial horizon studies). Evidence-based

**Figure 2:** Overview of expected grading of decision uncertainty (i.e., high to low) and strength of evidence (i.e., weak to strong) of early, preliminary (Pre) and full cost-utility analysis (CUA) conducted during typical health technology assessments at early, mid and late phase of product development (manufacturer’s perspective) and clinical acceptance (healthcare’s perspective) of prosthetic care innovations, respectively.
developments of new interventions takes time, particularly when the recommended clinical timelines are followed to demonstrate efficiency and safety (e.g., clinical trial registration, ethics approval, surgical learning curve, observation times, design of rehabilitation program). Several years might be needed to gather the costs and utilities required to complete primary and modelling CUAs. Consequently, mainstream CUAs can hardly inform promoters timely. Lack of timeliness is even more problematic with new prosthetic care technologies that are more susceptible to be superseded after five years. Gallego et al (2011) described decisions to approve technology by committees and regulatory bodies, such as the Australian Medical Services Advisory Committee, typically occurs after the technology has evolved or is already commonly being used in practice. Steuten (2011) also noted the problems with this approach, warning that many design decisions (e.g. target population, use setting, technology design features such as connectivity with data infrastructure, seamless integration with complementary technology, etc) are made in the early stages of product development and are difficult, expensive and/or impossible to change at a later date.

Several studies used a full CUA to assess consequences of the provision of socket based solution including advanced prosthetic components such as microprocessor-controlled knees and energy storing and return feet as well as socket-free solutions including bone-anchored prostheses. Preliminary cost-utility analyses

The issue of timeliness of full CUAs could be addressed by performing preliminary CUAs of innovations that could take place sometimes around the mid-stage of product development when clinical usage is still limited to small cohorts. Preliminary CUA is an option “in-between” early and full CUAs that considered innovations with a broad range of development status. Therefore, preliminary CUAs can be conducted using a wide spectrum of methods. They can involve primary data of actual (e.g., financial records) and/or simulated (e.g., purposely created schedules) costs expressed in monetary units as well as measured (e.g., quality of life surveys) and/or estimated (e.g., literature) utilities expressed in QALY for cohorts of participants over a somewhat lengthy time horizon.

The assumption was made that typical preliminary CUAs have a weak and moderate capacity to address 9 (33%) and 8 (30%) of items in the CHEERS checklist, including 7 (44%) and 6 (38%) of items in the Methods as well as 2 (40%) and 2 (40%) of items in the Results sections, respectively (Table 1). It was estimated that preliminary CUAs should be capable to address 11 (58%) of items in the CHEC-extended checklists (Table 2).

Resources needed to conduct preliminary CUAs could vary depending on the sources of data considered. Estimating costs from schedules and utilities from literature might require less resources than extracting costs from financial systems and utilities from a survey for a cohort of convenient sample size. Preliminary CUAs can provide some indications of probable consequences of innovations. Practically, preliminary CUAs can generate primary information, in part or in whole, useful for modelling CUAs (e.g., costs and utilities estimates, scenario drafting).

However, preliminary CUAs are usually built around substantial assumptions based on best-estimates of costs and utilities at the time. Typical preliminary CUAs are characterised by narrow perspective, simple scenarios, and time horizons tentatively shorter than full CUAs. Further limitations are inherent to the mismatch of costs and utilities from incongruous jurisdictions, onsets and post-operative timelines. For example, actual costs extracted from an healthcare financial system over several years might be considered against estimated utilities based on studies performed in other countries measuring quality of life six months after the intervention. Finally, uncertainty and sensibility of preliminary CUAs might be only loosely considered and reported. Altogether, the weight of these limitations on the strength of evidence is less known weakening the recommendations. Unfavourable outcomes of preliminary CUAs might, at least, question and, possibly, stop further product commercialization and clinical considerations. A decision must be made whether favourable outcomes are deemed sufficient to pursue and eventually, readjust further developments.

Recent examples of preliminary CUAs of innovations looked at the benefits of transfemoral and transtibial bone-anchored prostheses from government prosthetic care perspective. Early cost-utility analyses

Preliminary CUAs can provide timelier assessment than full CUAs. Nonetheless, there is a current trend in health economic literature arguing that preliminary CUAs are yet to provide sufficiently timely assessment of innovations. Hence, the promotion of early CUAs, also called “iterative economic evaluations” or “very early HTA” by Ijzerman and Steuten (2011), which pointed out that attempts have already been made, using “horizon scanning systems”, to include new, emerging technologies into health policy as it is developed. Other authors have referred to this as the use of “early warning systems”. Early CUAs tend to be constructed like preliminary CUAs but they rely more heavily on sparser costs and utilities data as well as sketched assumptions. These analyses tend to be based on best guestimates of most likely costs and utilities collected with case-series studies and/or extracted from the literature often produced outside the relevant jurisdiction.
Table 1: Expected capacity (i.e., weak, moderate, strong) of typical early, preliminary (Pre) and full cost-utility analysis (CUA) to address the 27-item of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.

| Section and item number | Recommendation | CUA       |
|------------------------|----------------|-----------|
|                        |                | Early | Pre | Full |
| **Title and abstract** |                |       |     |      |
| Title                  | Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared. | Strong | Strong | Strong |
| Abstract               | Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions. | Strong | Strong | Strong |
| **Introduction**       |                |       |     |      |
| Background and objectives | Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions. | Strong | Strong | Strong |
| **Methods**            |                |       |     |      |
| Target population and subgroups | Describe characteristics of the base case population and subgroups analysed, including why they were chosen. | Moderate | Moderate | Strong |
| Setting and location   | State relevant aspects of the system(s) in which the decision(s) need(s) to be made. | Moderate | Strong | Strong |
| Study perspective      | Describe the perspective of the study and relate this to the costs being evaluated. | Weak | Moderate | Strong |
| Comparators            | Describe the interventions or strategies being compared and state why they were chosen. | Weak | Moderate | Strong |
| Time horizon           | State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate. | Moderate | Moderate | Strong |
| Discount rate          | Report the choice of discount rate(s) used for costs and outcomes and say why appropriate. | Weak | Weak | Strong |
| Choice of health outcomes | Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed. | Weak | Weak | Strong |
| Measurement of effectiveness | Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data. | Weak | Weak | Strong |
| Measurement and valuation of preference based outcomes | If applicable, describe the population and methods used to elicit preferences for outcomes. | Weak | Weak | Strong |
| Estimating resources and costs | Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. | Weak | Weak | Strong |
| Currency, price date, and conversion | Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate. | Strong | Strong | Strong |
| Choice of model         | Describe and give reasons for the specific type of decision analytical model used. Providing a figure to show model structure is strongly recommended. | Moderate | Strong | Strong |
| Assumptions            | Describe all structural or other assumptions underpinning the decision-analytical model. | Weak | Moderate | Strong |
| Analytical methods     | Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. | Weak | Moderate | Strong |
Table 1 (continued).

| Section and item number | Recommendation                                                                 | CUA                        |
|-------------------------|--------------------------------------------------------------------------------|----------------------------|
|                         |                                                                                 | Early | Pre | Full |
| Study parameters        | Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended. | Weak  | Moderate | Strong |
| Incremental costs and outcomes | For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios. | Strong | Strong | Strong |
| Characterising uncertainty | Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective). | Weak  | Moderate | Strong |
| Characterising heterogeneity | Model-based economic evaluation: Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions. | Weak  | Weak | Strong |
| Study findings, limitations, generalisability, and current knowledge | Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge. | Strong | Strong | Strong |
| Other                   | Source of funding | Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support. | Strong | Strong | Strong |
|                         | Conflicts of interest | Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations. | Strong | Strong | Strong |

Table 2: Expected capacity (i.e., yes, no) of typical early preliminary (Pre) and full cost-utility analysis (CUA) to address the 19-item Consensus Health Economic Criteria (CHEC) extended checklist.

| Item | Questions                                      | CUA                        |
|------|------------------------------------------------|----------------------------|
|      |                                                | Early | Pre | Full |
| 1    | Is the study population clearly described?     | Yes   | Yes | Yes  |
| 2    | Are competing alternatives clearly described?  | Yes   | Yes | Yes  |
| 3    | Is a well-defined research question posed in answerable form? | Yes   | Yes | Yes  |
| 4    | Is the economic study design appropriate to the stated objective? | Yes   | Yes | Yes  |
| 5    | Is the chosen time horizon appropriate in order to include relevant costs and consequences? | No    | No  | Yes  |
| 6    | Is the actual perspective chosen appropriate?  | Yes   | Yes | Yes  |
| 7    | Are all important and relevant costs for each alternative identified? | No    | No  | Yes  |
| 8    | Are all costs measured appropriately in physical units? | Yes   | Yes | Yes  |
| 9    | Are costs valued appropriately?                | No    | No  | Yes  |
| 10   | Are all important and relevant outcomes for each alternative identified? | No    | No  | Yes  |
| 11   | Are all outcomes measured appropriately?       | No    | No  | Yes  |
| 12   | Are outcomes valued appropriately?             | No    | No  | Yes  |
| 13   | Is an incremental analysis of costs and outcomes of alternatives performed? | No    | Yes | Yes  |
| 14   | Are all future costs and outcomes discounted appropriately? | No    | No  | Yes  |
| 15   | Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis? | No    | No  | Yes  |
| 16   | Do the conclusions follow from the data reported? | Yes   | Yes | Yes  |
| 17   | Does the study discuss the generalizability of the results to other settings and patient/client groups? | Yes   | Yes | Yes  |
| 18   | Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)? | Yes   | Yes | Yes  |
| 19   | Are ethical and distributional issues discussed appropriately? | Yes   | Yes | Yes  |
It was assumed that usual early CUAs have a weak capacity to address 15 (56%) of items in the CHEERS checklist including 11 (69%) of items in the Methods as well as 4 (80%) of items in the Results sections (Table 1). Preliminary CUAs might be incapable to address up to 9 (47%) of items in the CHEC-extended checklists (Table 2).

Early CUAs are affordable and timely. They could help to reduce or validate assumptions subsequently used in preliminary or modelling CUAs. Perhaps, the most valuable return on investment of early CUAs is to provide insight into the viability of the product and worthiness of the clinical introduction on an innovation, as described by Kannenberg and Seidinger (2019). 38

As expected, outcomes of early CUAs are likely to have high uncertainty and sensibility leading to low level of evidence and only tentative recommendations. Early evidence of potential CUA might fast-track on-going innovation development. Limited prospects of CUA might raise questions about further allocation of resources to a product that has, ultimately, minimal chance to meet payer’s expectations.

| Strengths                                      | Weaknesses                                      |
|-----------------------------------------------|-------------------------------------------------|
| **Table 3**: Typical strengths and weaknesses of the early, preliminary, and full cost-utility analyses (CUA) of prosthetic care innovations. |
| **Full CUA**                                  | **Weaknesses**                                  |
| Address strongly all 27 CHEERS items           | Need of primary costs and utilities data         |
| Capable to address all 19 CHEC items           | Require substantial resources                    |
| Comprehensive list of scenarios                | Lack of timeliness                               |
| Scalable time horizon                          |                                                 |
| Strong understanding of uncertainty            |                                                 |
| Strong understanding of sensibility            |                                                 |
| High level of evidence                         |                                                 |
| Strong recommendations                         |                                                 |
| **Preliminary CUA**                           | **Weaknesses**                                  |
| Address strongly 37% of CHEER items            | Address weakly 33% of CHEER items                |
| Capable to address 58% of CHEC items           | Uncapable to address 42% of CHEC items           |
| Timeliness of information                      | Variability of resources required                 |
| Strong understanding of uncertainty            | Build around substantial assumptions              |
| Strong understanding of sensibility            | Rely on best-known evidence                       |
| High level of evidence                         | Consider narrow perspective                       |
| Strong recommendations                         | Consider plausible scenarios,                   |
|                                                 | Consider mid-term time horizon                   |
|                                                 | Mismatch costs and utilities data                |
|                                                 | Limited understanding of uncertainty             |
|                                                 | Limited understanding of sensitivity             |
|                                                 | Moderate level of evidence                        |
|                                                 | Moderate strength of recommendations             |
| **Early CUA**                                 |                                                 |
| Address strongly 30% of CHEER items            | Address weakly 56% of CHEER items                |
| Capable to address 53% of CHEC items           | Uncapable to address 47% of CHEC items           |
| Require little resources                       | Variability of resources required                 |
| Timeliness of information                      | Build around substantial assumptions              |
| Early insights into product viability          | Rely on best-known evidence                       |
| Early insights into clinical worthiness         | Consider narrow perspective                       |
| Identity evidence gaps                         | Consider hypothetical scenarios,                 |
| Provide headroom for improvement               | Consider short-term time horizon                  |
| Educate design of preliminary CUAs             | Low understanding of uncertainty                  |
| Fast-track approval                             | Low understanding of sensitivity                  |
|                                                 | Low level of evidence                             |
|                                                 | Low strength of recommendations                   |
HEALTH ECONOMIC EVALUATIONS OF PROSTHETIC CARE INNOVATIONS

obstacles must be overcome before earlier and, more particularly, preliminary CUA's of prosthetic care innovations would be routinely carried out by promoters.

One critical obstacle is the abundance of methods. Ijzerman and Steuten (2011) listed ten quantitative methods that could be used in earlier HTA (e.g., payback from research analysis, strategic business cases, health impact assessment, multi-criteria decision methods, choice-based preference methods, real options analysis, early health economic modelling, horizon scanning systems, clinical trial simulation, value-of-information analysis). 37

Another obstacle is the multiple pathways for HEE relying on the same level of clinical evidence of utilities (Figure 2). Logically, early and full CUA's are indicated at early stage and after clinical acceptance, respectively. Initial clinical evidence provided by proof of utility and case-series could be used to perform an early and preliminary CUA's. Stronger evidence gathered during cohort study and clinical trial might be deemed sufficient to conduct a preliminary or full CUA's.

Disparities of methods and constructs of earlier CUA's (e.g., perspective, time horizon, discount, uncertainty, sensibility) have ripple effects limiting implementation of earlier CUA's. Cross-comparing outcomes of earlier CUA's between innovations might be challenging to interpret. Generalization of outcomes across healthcare organisations might be limited. Earlier CUA's might show a broad level of quality when appraised with standard CHEERS and CHEC-extended checklists, primarily designed for full CUA's (Table 1, Table 2). Altogether, disparity of outcomes also makes earlier CUA's scoring modestly in these checklists less likely to be published. The result of this is a sparsity of publications in prosthetic-focused scientific journals, let alone health economics journals, the latter of which are inclined to consider that socio-economic research in prosthetics is for a niche audience. Literature review and meta-analyses of health economic evaluations failing to stratify publications accordingly to the three types of CUA's might appraise unfavourably the contribution of earlier CUA's. Therefore, this review might skew the perception on the overall quality of health economic evaluations of prosthetic care. Earlier CUA's might score less not because they are poorly done but because they are dealing with more unreliable datasets.

Opportunities for basic framework of preliminary CUA

On a one side, every innovation is different. Each healthcare organisation has particular expectations. Promoters might choose a specific pathway for a given CUA depending on their confidence to make valid assumptions. Therefore, a preliminary CUA of an innovation could be unique.

One the other side, provision of prosthetic care follows a rather standardized process. Reimbursement are often made for categories of components (e.g., microprocessor-controlled knees). Prosthetists performed series of well-identified specific tasks related to prosthetic fitting (e.g., fitting of socket, choice of components, alignment of prosthesis), assessment of outcomes (e.g., comfort, stability, mobility) and reporting to payers (e.g., reimbursement claims). Indeed, each of these tasks is sufficiently codified to be individually supported by healthcare organisations (e.g., L-Codes). This means that most preliminary CUA's relying on estimated rather than primary costs could apply a template of schedule of allowable expenses. This typical matrix can present costs at the intersections of list of tasks in rows and timeline of interventions in columns (APPENDIX 1). Ideally, disruptive and economical innovations changing best prosthetic care practice should affect a schedule by reducing the price tag and/or the frequency of one or more tasks.

Furthermore, standard assessments are commonly used to quantify outcomes of prosthetic fittings using self-reported satisfaction (e.g., Orthotics and Prosthetics User's Survey, Quebec User Evaluation of Satisfaction with Assistive Technology, socket prosthetic comfort score), physical tasks (e.g., Berg Balance Scale, timed get-up and go, walking speed, 2-minute walk, 6-minute walk, functional ambulation profile, amputee mobility predictor with prosthesis) as well as specific (e.g., Questionnaire for Persons with a Translimbal Amputation) and generic (e.g., EQ-5D, SF36) health-related quality of life with an innovation.

Altogether, organisation of the delivery and assessment of prosthetic care might be sufficiently transferable across innovations to consider a more uniform approach to preliminary CUA's. This creates opportunities to explore the development of a basic framework including set
constructs (e.g., perspective, time horizon, discount) and practical recommendations (e.g., funding cycles) specific to preliminary CUAs of the prosthetic care innovations (APPENDIX 1). This new approach to a preliminary CUA has the potential to simplify the selection of methods, standardise outcomes, ease comparisons between innovations and streamline pathways for adoption while facilitating the production of a body of literature on prosthetic health economics.

CONCLUSION

This work showed that promoters must make complex decisions when attempting to establish the socio-economic values of prosthetic care innovations. It is commonly acknowledged that a unique type of CUA could not be applied at every stage of development of an innovation. Preliminary CUAs of innovations at the mid-stage of development is particularly valuable but challenging. Boundaries delineating preliminary CUAs from early and full CUA might be blurry pushing promoters to consider a wide range of methods.

The outcomes suggest that there are opportunities for collective design of a basic framework of a preliminary CUA of prosthetic care innovations. However, reaching consensus around a framework can be challenging because there is no formal forum capable to organise discussions outside of usual scientific peer-review channels. There is a need for an ad-hoc reference group involving promoters and health economists specialized in prosthetics and medical aids. Ideally, this working group should be hosted by international (e.g., World Health Organisation Standards for Prosthetics and Orthotics Service Provision, International Society for Prosthetics and Orthotics) or national (e.g., American Orthotic and Prosthetic Association, Center for Orthotic and Prosthetic Learning and Outcomes/Evidence-Based Practice) governing bodies. Its missions could be to develop guidelines and, possibly, standards of HEEs of prosthetic care interventions including preliminary CUAs frameworks (e.g., set constructs, practical recommendations).

Ultimately, a wide adoption of a this collegial preliminary CUA framework will, hopefully, contribute to promote the routinely used preliminary CUA. It is anticipated that this framework should facilitate access to economical prosthetic care solutions improving the life of individuals suffering from limb loss worldwide.

CALL TO ACTION

• Gather an ad-hoc reference group capable of (A) monitoring the current trends in HEEs of new healthcare technologies, (B) develop guidelines and, possibly, standards of HEEs of prosthetic care interventions, (C) promote the adoption of these guideline (e.g., publications of position papers, presentations at conferences).

• This working group could facilitate discussions between promoters of prosthetic care innovations around the use and validation of preliminary CUAs frameworks.

• Practically, these discussions should focus on the development of basic framework of a preliminary CUAs, more particularly set constructs and practical recommendations.

ACKNOWLEDGEMENTS

The author wishes to express his gratitude to Debra Berg and Gregory Merlo for their support.

DECLARATION OF CONFLICTING INTERESTS

The author is in the view that these competing interests do not conflict with the content of this manuscript. Laurent Frossard, Director and Chief Scientist Officer of YourResearchProject Pty Ltd, has worked as consultant for several organisations on non-related educational programs and projects of research focusing on recording loading data, developing of database to record clinical outcomes as well as drafting grants and manuscripts for Cognitive Institute, Exercise & Sports Science Australia, Griffith University, iPug Pty Ltd, Middlesex University, New Zealand Artificial Limb Service, Osseointegration Group of Australia Pty Ltd, OSSUR, Poly-Orthodox International, Queensland Artificial Limb Service, Queensland University of Technology, Return to Work South Australia, South Australia Health, Tequir S.L., University of the New South Whales, University of the Sunshine Coast.

SOURCES OF SUPPORT

This study was funded by YourResearchProject Pty Ltd.

REFERENCES

1. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. WHO guide to cost-effectiveness analysis [Internet]. World Health organisation. 2003; [Cited 2021, June 9]. Available from: https://www.who.int/choice/publications/p_2003_generalised_cea.pdf?ua=1DFID
2. Paternò L, Ibrahim E, Grupponi E, Menciassi A, Ricotti L. Sockets for Limb Prostheses: A Review of Existing Technologies and Open Challenges. IEEE Trans Biomed Eng. 2018; 65(9): 1996-2010. DOI: 10.1109/tbme.2017.2775100
3. Klenow TD, Kahle JT, Fedel FJ, Ropp J, Highsmith MJ. Comparative Efficacy of Transfemoral Prosthetic Interfaces. J Prosthet Orthot. 2017; 29(3): 130-136. DOI: 10.1097/ jpo.000000000000135
4. Frossard L, Laux S, Lee Gow D, Berg D. Role of the prosthetist in provision of bone-anchored prostheses: governmental and practitioner perspectives. The AOPA Review. 2018; 3(1):26-27. https://eprints.qut.edu.au/123164/
5. Raschke SU, Orendurf MS, Mattie JL, Kenyon DE, Jones OY, Moe D, et al. Biomechanical characteristics, patient preference and
activity level with different prosthetic feet: a randomized double blind trial with laboratory and community testing. J Biomech. 2015; 48(1): 146-52. DOI: 10.1016/j.jbiomech.2014.10.002

6.Turner S, McGregor AH. Perceived effect of socket fit on major lower limb prosthesis rehabilitation: A clinician and amputee perspective. Archives of Rehabilitation Research and Clinical Translation. 2020; 2(3): 100059. DOI: 10.1682/jrrd.2020.100059

7.Collins DM, Karmarkar A, Relich R, Pasquina PF, Cooper RA. Review of research on prosthetic devices for lower extremity amputation. Curr Rev Biomed Eng. 2006; 34(5): 379-438. DOI: 10.1615/critrevbiomedeng.v34.i5.20

8.Van der Linde H, Hofstad CJ, Geurts AC, Postema K, Geertzen JH, van Limbeek J. A systematic literature review of the effect of different prosthetic components on human functioning with a lower-limb prosthesis. J Rehabil Res Dev. 2004; 41(4): 555-70. DOI: 10.1682/jrrd.2003.06.0102

9.Samuelsson KA, Töyäri O, Salminen AL, Brandt Å. Effects of lower limb prosthesis on activity, participation, and quality of life: a systematic review. Prosthet Orthot Int, 2012. 36(2):145-58. DOI: 10.1177/0309364611432794

10.Webster JB, Hakimi KN, Williams RM, Turner AP, Norvell DC, Czerniecki JM. Prosthetic fitting, use, and satisfaction following lower-limb amputation: a prospective study. J Rehabil Res Dev. 2012; 49(10):1493-504. DOI: 10.1682/jrrd.2012.01.0001

11.Ghilberet J, De Bock S, Flynn L, Geeroms J, Tassinbon B, Roelands B, et al. Guidelines and recommendations to investigate the efficacy of a lower-limb prosthetic device: a systematic review. IEEE Trans. Med. Robot. Bionics. 2019; 1(4):279-296. DOI: 10.1109/tmrb.2019.2949855

12.Dillingham TR, Pezzin LE, MacKenzie EJ, Burgess AR. Use and satisfaction with prosthetic devices among persons with traumatic-related amputations: a long-term outcome study. Am J Phys Med Rehabil. 2001; 80(8): 563-71. DOI: 10.1097/00008526-200108000-00003

13.Pezzin LE, Dillingham TR, MacKenzie EJ, Ephraim P, Rossbach P. Use and satisfaction with prosthetic limb devices and related services. Arch Phys Med Rehabil. 2004; 85(5): 723-9. DOI: 10.1016/j.apmr.2003.06.002

14.Campbell JH, Stevens PM, Wurdean SR. OASIS 1: Retrospective analysis of four different microprocessor knee types. RATE. 2020;1-10. DOI: 10.1177/2055668320968476

15.Bui KM, Raugi GJ, Nguyen VQ, Reiber GE. Skin problems in individuals with lower-limb loss: literature review and proposed classification system. J Rehabil Res Dev. 2009; 46(9): 1085-90. DOI: 10.1682/jrrd.2009.04.0052

16.Kahle JT, Kienow TD, Highsmith MJ. Comparative effectiveness of an adjustable transfemoral prosthetic interface accommodating volume fluctuation: case study. Technology and Innovation. 2016; 18(2-3): 175-183. DOI: 10.21300/18.2-3.2016.175

17.Gholizadeh H, Abu Osman NA, Eshraghi A, Arifin N, Chung TY. A comparison of pressure distributions between two types of sockets in a bulbous stump. Prosthet Orthot Int. 2016; 40(4):509-16. DOI: 10.1177/0309364614564022

18.Meulenbelt HE, Geertzen JH, Jonkman MF, Dijkstra PU. Determinants of skin problems of the stump in lower-limb amputees. Arch Phys Med Rehabil. 2009; 90(1): 74-81. DOI: 10.1016/j.apmr.2008.07.015

19.Schaffalitzky E, Gallagher P, Maclachlan M, Ryall N. Understanding the benefits of prosthetic prescription: exploring the experiences of practitioners and lower limb prosthetic users. Disabil Rehabil. 2011; 33(15-16):1314-23. DOI: 10.3109/09638288.2010.529234

20.Jordan RW, Marks A, Higman D. The cost of major lower limb amputation: a 12-year experience. Prosthet Orthot Int. 2012; 36(4):430-4. DOI: 10.1177/0309364612441499

21.Boone DA. The economic value of mobility with a prosthesis. J Prosthet Orthot. 2019; 31(1S). DOI: 10.1097/JPO.0000000000002321

22.Fish D. The Development of Coverage Policy for Lower Extremity Prosthetics: The Influence of the Payer on Prosthetic Prescription. J Prosthet Orthot. 2006; 18(6):125-129. DOI: 10.1097/00008526-200601000-00017

23.Papaioannou G, Mitrogiannis C, Nianios G, Fiedler G. Assessment of amputee socket–stump–residual bone kinematics during strenuous activities using Dynamic Roentgen Stereogrammetric Analysis. J Biomech. 2010; 43(5):871-878. DOI: 10.1016/j.jbiomech.2009.11.013

24.Zheng YP, Mak AF, Leung AK. State-of-the-art methods for geometric and biomechanical assessments of residual limbs: a review. J Rehabil Res Dev. 2001; 38(5):487-504.

25.Gholizadeh H, Osman NA, Eshraghi A, Ali S. Transfemoral prosthesis suspension systems: a systematic review of the literature. Am J Phys Med Rehabil. 2014; 93(9): 809-23. DOI: 10.1097/PHM.0000000000000094

26.Gerzina C, Potter E, Haleem AM, Dabash S. The future of the amputees with osseointegration: A systematic review of literature. J Clin Orthop Trauma. 2020; 11(Suppl 1): S142-S148. DOI: 10.1016/j.jcot.2019.05.025

27.Potter BK. From bench to bedside: we can (still) do better: An annual review of research on prosthetic devices for lower extremity amputees provided by government organization. Data in Brief. 2019; 26:104536. DOI: 10.1016/j.dib.2019.104536

28.Overmann AL, Forsberg JA. The state of the art of osseointegration for limb prosthesis. Biomed Eng Lett. 2019; DOI: 10.1007/s13534-019-00133-9

29.Frossard L, Hagberg K, Häggström E, Gow DL, Brännmark R, Peary M. Functional outcome of transfemoral amputees fitted with an osseointegrated fixation: Temporal gait characteristics. J Prosthet Orthot. 2010; 22(1): 11-20. DOI: 10.1097/JPO.0b013e3181ccc53d

30.Frossard L, Ferrada L, Berg D. Survey data on the quality of life of consumers fitted with osseointegrated fixation and bone-anchored limb prostheses provided by government organization. Disabil Rehabil. 2021; 43(1):1-11. DOI: 10.1080/09638288.2019.164346

31.Helsgaon B, Pålsson H, Rünnarson TP, Frossard L, Viceconti M. Risk of failure during gait for direct skeletal attachment of a femoral prosthesis: a finite element study. Med Eng Phys. 2009; 31(5):595-600. DOI: 10.1016/j.medengphy.2008.11.015

32.Frossard L, Hagberg K, Hagberg K, Brännmark R, Load L. Application of a bone-anchored transfemoral prosthesis: characterisation of prosthetic components – A pilot study. J Rehabil Res Dev. 2013; 50(5): 619–634. DOI: 10.1682/JRRD.2012.04.0062
33. Frossard L, Leech B, Pitkin M. Automated characterization of anthropomorphy of prosthetic feet fitted to bone-anchored transfalstibial prostheses. IEEE Trans Biomed Eng. 2019; 66(12): 3402-3410. DOI: 10.1109/TBME.2019.2904713

34. Frossard L, Leech B, Pitkin M. Loading applied on osseointegrated implant by transfalstibial bone-anchored prostheses during daily activities: Preliminary characterization of prosthetic feet. J Prosthet Orthot. 2020; 32(4):258-271. DOI: 10.1097/jpo.0000000000000289

35. Highsmith MJ, Kahle JT, Lewadowski A, Klenow TD, Oriola JJ, Miro RM, et al. Economic evaluations of interventions for transfalstibial amputees: A scoping review of comparative studies. Technol Innov. 2016;18(2-3):85-98. DOI: 10.21300./18.2-3.2016.85.

36. Tai BB, Bae YH, Le QA. A systematic review of health economic evaluation studies using the patient’s perspective. Value Health. 2016; 19(6): 903-908. DOI: 10.1016/j.jval.2016.05.010

37. Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy. 2011; 9(5):331-47. DOI: 10.2165/11593380-00000000-0000

38. Kannenberg A, Seidinger S. Health economics: the perspective of a prosthetic manufacturer. J Prosthet Orthot. 2019; 31(1S). DOI:10.1097/JPO.000000000000234

39. Esraghi A, Osman NA, Gholizadeh H, Karimi M, Ali S. Pistoning assessment in lower limb prosthetic sockets. Prosthet Orthot Int. 2012; 36(1):25-44. DOI: 10.1017/S030936461431625

40. Frossard LA, Tranberg R, Haggstrom E, Pearcy M, Bränemark P. Load on osseointegrated fixation of a transfalstibial amputee during a fall: loading, descent, impact and recovery analysis. Prosthet Orthot Int. 2010; 34(1): 85-97. DOI: 10.3109/03093640903585024

41. Osseointegrated prosthetic implants for people with lower-limb amputation: a health technology assessment [Internet]. Ont Health Technol Assess Ser. 2019;[Cited 2021, June 9]. Available from: http://www.hqontario.ca/evidence-to-improve-care/journalontario-health-technology-assessment-series

42. Martin R. Rapid review of osseointegration/ direct skeletal fixation-A report for NHS England [Internet]. Bazian Ltd: UK; 2016; [Cited 2021, June 9]. Available from: https://www.ispo.org.uk/resources/Bazian-Report-pdf

43. Amsan AN, Nasution AK, Riau P, Ramlee MH. A short review on the cost, design, materials and challenges of the prosthetics leg development and usage. International Conference of CELSciTech 2019-Science and Technology track (ICCELST-ST 2019) 2019; 59-64. DOI:10.2991/iccelst-st.19.2019.12

44. Kaulback K, Jones A. Osseointegrated prosthetic implants for lower limb amputation: A review of clinical effectiveness, cost-effectiveness and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017; [Cited 2021, June 9]. Available from: https://pubmed.ncbi.nlm.nih.gov/28825780/

45. Frossard L, Ferrada L, Berg D. Survey on the quality of life of consumers fitted with osseointegrated fixation and bone-anchored limb prostheses provided by government organization. 2019; Mendeley data. DOI: 10.17632/bktxxmrth.1

46. Frossard L, Ferrada L, Quincey T, Burkett B, Berg D. Development of a Government Continuous Quality Improvement Procedure for Assessing the Provision of Bone Anchored Limb Prosthesis: A Process Re-Design Descriptive Study. Can Prosthet Orthot J. 2018; 1(2). DOI: 10.33137/cpoj.v1i2.31326

47. Frossard L, Merlo G, Quincey T, Burkett B, Berg D. Development of a procedure for the government provision of bone-anchored prostheses using osseointegration in Australia. PharmacoEconomics. 2017; 1(4): 301-314. DOI:10.1007/s41669-017-0032-5

48. Stevens PM, Highsmith MJ, Sutton B. Measuring value in the provision of lower-limb prostheses. J Prosthet Orthot. 2019; 31(1S). DOI:10.1097/JPO.0000000000000232

49. Frossard L, Debra B. Australian innovations of health services and economic evaluation of bone-anchored prostheses using osseointegration, in Australian Orthotic Prosthetic Association (AOPA) Congress. 2017; Melbourne, Australia.

50. Frossard L, Ferrada L, Quincey T, Berg D. Cost-Effectiveness of Transtibial Bone-Anchored Prostheses Using Osseointegrated Fixation. J Prosthet Orthot. 2021; DOI: 10.1097/jpo.00000000000372

51. Frossard L, Berg D, Merlo G, Quincey T, Burkett B. Cost comparison of socket-suspended and bone-anchored transfalstibial prostheses. J Prosthet Orthot. 2017; 29(4):150-160. DOI: 10.1097/JPO.00000000000142

52. Frossard LA, Merlo G, Burkett B, Quincey T, Berg D. Cost-effectiveness of bone-anchored prostheses using osseointegrated fixation: Myth or reality? Prosthet Orthot Int. 2018; 42(3):318-327. DOI: 10.1177/0309364617740239

53. Frossard L. Data supporting the 2019 Queensland Artificial Limb Service’s science report about innovations of health services and economic evaluation of limb lower bone-anchored prostheses. 2020; Mendeley data. DOI:10.17632/3b6wtdt8x.1

54. O’Malley SP. Issues facing the Australian Health Technology Assessment Review of medical technology funding. Med J Aust. 2010; 193(1): 30-3. DOI: 10.5694/j.1326-5377.2010.tb03737.x

55. Bertram MY, Lauer JA, De Jonchere E, Edejer T, Huibbessy R, Kiery MP, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016; 94(12): 925-930. DOI: 10.2471/BLT.15.164418

56. Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol. 2008; 52(25): 2119-26. DOI: 10.1016/j.jacc.2008.09.018

57. Cape J, Beca J, Hoch J. Introduction to cost-effectiveness analysis for clinicians. Univ Tor Med. 2013; 90(3): 103-105.

58. Drummond M, Tarricone R, Toribica A. Incentivizing research for the effectiveness of medical devices. Eur J Health Econ. 2016; 17(9): 1055-1058. DOI: 10.1007/s10198-016-0820-3

59. Armstrong BK, Gillespie JA, Leeder SR, Rubin GL, Russell LM. Challenges in health and health care for Australia. Med J Aust. 2007; 187(9): 495-9.

60. Gallego G, Casey R, Norman R, Goodall S. Introduction and uptake of new medical technologies in the Australian health care system: a qualitative study. Health Policy. 2011; 102(2-3): 152-8. DOI: 10.1016/j.healthpol.2011.04.003
HEALTH ECONOMIC EVALUATIONS OF PROSTHETIC CARE INNOVATIONS

61. Frossard L, Debra B. Australian innovations of health services and economic evaluation of bone-anchored prostheses using osseointegration, in Australian Orthotic Prosthetic Association (AOPA) Congress. 2017; Melbourne, Australia.

62. Haggstrom EE, Hansson E, Hagberg K. Comparison of prosthetic costs and service between osseointegrated and conventional suspended transfemoral prostheses. Prosthet Orthot Int. 2013; 37(2):152-60. DOI: 10.1177/0309364612454160

63. Hansson E, Hagberg K, Cawson M, Brodkorb TH. Patients with unilateral transfemoral amputation treated with a percutaneous osseointegrated prosthesis: a cost-effectiveness analysis. Bone Joint J. 2018; 100-B(4):527-534. DOI: 10.1302/0301-620X.100B4.BJ-J.2017-0968.R1

64. Brodkorb TH, Henriksen M, Johannesen-Munk K, Thidel F. Cost-effectiveness of C-leg compared with non-microprocessor-controlled knees: a modeling approach. Arch Phys Med Rehabil. 2008; 89(1): 24-30. DOI: 10.1016/j.apmr.2007.07.049

65. Gerzeli S, Tornica A, Fattore G. Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees. Eur J Health Econ. 2009; 10(1): 47-55. DOI: 10.1007/s10198-008-0102-9

66. Cutti AG, Lettieri E, Del Maestro M, Radaelli G, Luchetti M, Verni G, et al. Stratified cost-utility analysis of C-Leg versus mechanical knees: Findings from an Italian sample of transfemoral amputees. Prosthet Orthot Int. 2017; 41(3):227-236. DOI: 10.1177/0309364616637955

67. Chen C, Hanson M, Chaturvedi R, Mattke S, Hillestad R, Liu HH. Economic benefits of microprocessor controlled prosthetic knees: A modeling study. J Prosthet Orthot. 2019; 31(1S)

68. Normann E, Olsson A, Brodkorb TH. Modular socket system versus traditionally laminated socket: a cost analysis. Prosthet Orthot Int. 2011; 35(1): 76-80. DOI: 10.1177/0309364610392812

69. Cutti AG, Lettieri E, Verni G. Health technology assessment as theoretical framework to assess lower-limb prosthetics—issues and opportunities from an international perspective. J Prosthet Orthot. 2019; 31(15):55-73. DOI: 10.1097/jpo.0000000000000235

70. Gordon R, Magee C, Frazier A, Evans C, McCosker K. An interim prostheses program for lower limb amputees: comparison of public and private models of service. Prosthet Orthot Int. 2010; 34(2): 175-83. DOI: 10.3109/03093646103510980

71. Datta D, Harris I, Heller B, Howitt J, Martin R. Gait, cost and time implications for changing from PTB to ICEX sockets. Prosthet Orthot Int. 2004; 28(2):115-20. DOI: 10.1080/03093640408726696

72. Highsmith MJ, Kahle JT, Wernke MM, Carey SL, Miro RM, Lura DJ, et al. Effects of the Genium knee system on functional level, stair ambulation, perceptive and economic outcomes in transfemoral amputees. Technol Innov. 2016; 18;2(3): 139-150. DOI: 10.21300/18.2-3.2016.139

73. Seelen HA, Hemmen B, Schmeets AJ, Ament AJ, Evers SM. Costs and consequences of a hemepha in an electronically stance and swing phase controlled knee joint. Technol Disabil. 2009; 21(1,2): 25-34. DOI: 10.3233/TAD-2009-0269

74. Selles RW, Janssens PJ, Jongenengel CD, Bussmann JB. A randomized controlled trial comparing functional outcome and cost efficiency of a total surface-bearing socket versus a conventional patellar tendon-bearing socket in transtibial amputees. Arch Phys Med Rehabil. 2005; 86(1):154-61; quiz 180. DOI: 10.1016/j.apmr.2004.03.036

75. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013; 16(2): 231-50. DOI: 10.1016/j.jval.2013.02.002

76. Van Mastrigt GA, Hiligsmann M, Arts JJ, Broos PH, Kleijnen J, Evers SM, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016; 16(6): 689-704. DOI: 10.1080/14737167.2016.1246960

77. Gerkens S, Crott R, Cleempot I, Thissen JP, Clason MC, Horsmans Y, et al. Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity. Int J Technol Assess Health Care. 2008; 24(3): 318-25. DOI: 10.1017/s026642308080422

78. Edwards DS, Phillip RD, Bosanquet N, Bull AM, Clasper JC. What is the magnitude and long-term economic cost of care of the British Military Afghanistan Amputee Cohort? Clin Orthop Relat Res. 2015; 473(9):2848-55. DOI: 10.1007/s11999-015-4250-9

79. Dobson A, El-Gamil A, Shimer M, DanVanzo JE. Economic value of prosthetic services among medicare beneficiaries: A claims-based retrospective cohort study, 2011-2014. J Neuroeng Rehabil. 2018;5;15(1):55. DOI: 10.1186/s12984-018-0406-7

80. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13(4): 322-38. DOI: 10.1177/0272989x9301300409

81. Blough DK, Hubbard S, McFarland LV, Smith DG, Gambel JM, Reiber GE. Prosthetic cost projections for servicemembers with major limb loss from Vietnam and OIF/OEF. J Rehabil Res Dev. 2010; 47(4): 387-402. DOI: 10.1682/jrd.2009.04.0037

82. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994; 3(2): 95-104. DOI: 10.1002/hec.4730030206

83. Basu A. and M.L. Maciejewski, Choosing a Time Horizon in Cost and Cost-effectiveness Analyses. JAMA. 2019. 321(11): p. 1096. DOI: 10.1001/jama.2019.1153.

84. Wijnen BF, Van Mastrixt GA, Redekop WK, Majioie HJ, De Kinderen RJ, Evers SM. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3). Expert Rev Pharmacoecon Outcomes Res. 2016; 16(6): p. 723-732. DOI: 10.1080/14737167.2016.1246961

85. Thielen FW, Van Mastroit GA, Burgers LT, Bramer WM, Majioie HJ, Evers SM, et al. How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Expert Rev Pharmacoecon Outcomes Res. 2016. 16(6): p. 705-721. DOI: 10.1080/14737167.2016.1246962

86. Frossard L, Stevenson N, Sullivan J, Uden M, Pearsy M. Categorization of activities of daily living of lower limb amputees during short-term use of a portable kinetic recording system: A
preliminary study. J Prosthet Orthot. 2011; 23(1): 2-11. DOI: 10.1097/JPO.0b013e318207914c

AUTHOR SCIENTIFIC BIOGRAPHY

Dr Laurent Frossard is a bionic limbs scientist who is passionate about developing ground-breaking prosthetic solutions to improve the lives of individuals suffering from limb loss. He is internationally recognized as a researcher and an independent expert for his unique expertise in bionic limbs. He approaches bionic solutions from a holistic perspective, by integrating the prosthetic biomechanics, clinical benefits, service delivery, and health economics. Dr Frossard has over 25 years of experience, both in academia and in private industries in Australia, Canada, and Europe. He has collaborated with over 100 organizations worldwide. He is currently a Professor of bionics at the Griffith University, the Director and Chief Scientist Officer at YourResearchProject Pty Ltd, and Adjunct Professor at the Queensland University of Technology and the University of Sunshine Coast in Australia.
### APPENDIX 1: Definition of key terms

| Term                                                                 | Definition                                                                                                                                                                                                 |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Basic framework of preliminary cost-utility analysis                | Generic canvas of preliminary cost-utility analysis including set constructs specific to prosthetic care innovations                                                                                 |
| Cost-effectiveness analysis                                         | Form of economic analysis that compares the relative costs expressed in monetary value and particular functional outcome of a treatment (e.g., walking speed)                                           |
| Cost-utility analysis                                               | Form of economic analysis that compares the relative costs expressed in monetary value and health effects of various interventions converted into utilities expressed quality-adjusted life-year                        |
| Health economic evaluation                                          | Comparative assessment of costs and outcomes of alternative health care technologies or health strategies providing incremental cost-outcome ratio, the relation of the estimated additional costs and the estimated additional outcome saved or lost by using an alternative health care technology |
| Health technology assessment                                        | Systematic evaluation of the properties and effects of a health technology, addressing the direct and intended effects of this technology, as well as its indirect and unintended consequences, and aimed mainly at informing decision making regarding health technologies |
| Modelling cost-utility analysis                                     | Form of analysis projecting of cost-utility based on decision-analytic models involving Bayesian or Markov models generally using plausible information extracted from primary studies                        |
| Primary cost-utility analysis                                       | Form of analysis relying on actual costs extracted from financial records expressed in monetary units or actual utilities measured by quality of life surveys converted into quality-adjusted life-year                 |
| Promoters of prosthetic care interventions                          | Groups developing and encouraging prosthetic care interventions including individuals suffering from limb loss (users’ perspectives), providers of prosthetic solutions (manufacturers’ perspective), rehabilitation and prosthetic specialists (clinicians’ perspective) and administrators of healthcare organisations (taxpayers’ perspective) |
| Prosthetic care innovation                                          | New intervention susceptible to alleviate clinical shortcomings and financial burden of current prosthetic fitting options                                                                               |
| Schedule of allowable expenses                                      | Matrix of costs (monetary units of talk) at the intersection of rows corresponding to lists of tasks (type of expenses) and columns corresponding to onsets of tasks (time of expenses)                          |
| Uncertainty and sensibility of health economic evaluations          | The size of the errors around the estimates of costs and utilities due to data sources (e.g., sample size) and/or to the process of evaluation (Markov modelling). |

Frossard L, Trends and opportunities in health economic evaluations of prosthetic care innovations. Canadian Prosthetics & Orthotics Journal. 2021; Volume 4, Issue 2, No.9. https://doi.org/10.33137/cpoj.v4i2.36364